Statistics for Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial
Total visits
| views | |
|---|---|
| Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial | 68 |
Total visits per month
| views | |
|---|---|
| November 2023 | 0 |
| December 2023 | 0 |
| January 2024 | 0 |
| February 2024 | 0 |
| March 2024 | 0 |
| April 2024 | 0 |
| May 2024 | 0 |
File Visits
| views | |
|---|---|
| Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer Phase 2 clinical KEYNOTE-059 trial.pdf | 14 |
Top country views
| views | |
|---|---|
| United States | 46 |
| Chile | 9 |
| Israel | 2 |
| Mexico | 1 |
Top city views
| views | |
|---|---|
| Miami | 36 |
| Santiago | 8 |
| Alameda | 7 |
| Tel Aviv | 2 |
| Campbell | 1 |
| Chicago | 1 |
| Sacramento | 1 |
| Zapopan | 1 |